July 31, 2018

SciBac Awarded up to $3.76M by CARB-X to Develop Hybrid Microbes as a Drug for C. diff

SciBac has been awarded up to $3.76 million in non-dilutive funding by CARB-X, a public-private partnership devoted to accelerating early medical R&D to combat the rising threat of antibiotic resistant Superbugs. This award supports development of SciBac’s novel biotherapeutic to treat and prevent Clostridium difficile infections (CDI). 


January 28, 2018

Startup Fire Interview with SciBac CEO Jeanette Mucha

Learn all about CEO Jeanette Mucha, the story of how SciBac was founded, MERGE technology, and the biotherapeutic pipeline that harnesses the microbiome to tackle antibiotic resistant diseases.


January 27, 2018

SciBac to present at The Human Microbiome: Time for Effective Translation

SciBac to present at 11:15 am, March 30 2018 at UCLA California Nanosystems Institute, Los Angeles, CA.


January 1, 2018

SciBac to present at Biotech Showcase on Jan 10

SciBac CEO, Jeanette Mucha, to present at the Biotech Showcase™ Annual Conference on January 10, 2018, 1:45pm at Hilton Union Square, Room Franciscan -  A.


September 19, 2017

SciBac Issued Patent for its Platform MERGE Technology

U.S. patent just issued for SciBac's "Method for Producing Chimeric Microbial Hybrids."


July 18, 2017

SciBac Announces Strain Development Project with Novozymes

SciBac will use its MERGE technology platform to develop non-GMO hybrid microorganisms for the purpose of creating a cost-efficient expression of enzymes for Novozymes.


May 3, 2017

BIO Announces 2017 Start-Up Stadium Finalists

Empowering the Cutting-Edge Companies of Tomorrow, Today SciBac announced as a finalist, having been judged by experts with entrepreneurial, investment, start-up, economic development, capital formation, and academic backgrounds from both the public and private sectors.


Apr 13, 2017

Thiel’s Breakout Labs fuels four new life science companies

Jeanette Mucha, CEO of SciBac, said: “The Breakout Labs grant will allow us to further advance our C. diff program, developing a live biotherapeutic that can destroy the harmful C. diff pathogen without antibiotics, while nurturing a healthy gut microbiome.”